This site is intended for health professionals only
Monday 27 May 2019
Share |

Increased mortality with darbepoetin

Negative results of a phase III trial now available

A phase III randomised, placebo-controlled study assessing the efficacy and safety of darbepoetin in cancer patients with anaemia not associated with chemotherapy has shown increased mortality in patients treated with this drug.

Amgen has notified the oncology medical community of the results of this trial. The study duration was 16 weeks, with a 16-week extension to enable further data on safety and effectiveness to be collected. Final analysis did not show a statistically significant effect of darbepoetin on the primary efficacy endpoint, with an incidence of red blood cell transfusions of 24% in the placebo vs 18% in the darbepoetin group. With a median survival follow-up of 4.3 months, the absolute number of deaths was found to be greater in the darbopoetin group (49% vs 46% in the placebo group). Follow-up for overall survival is continuing.

Amgen has stressed that darbepoetin is currently only approved for the treatment of patients with anaemia caused by chemotherapy.

Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher